Ipertrofan (Mepartricin)

Mepartricin binds to the bacterial 50S ribosomal subunit, blocking protein synthesis and exerting antibacterial effects. In prostatic tissue it also dampens inflammatory pathways, decreasing cytokine release and reducing local swelling, which contributes to symptom improvement.

The specific dosage and regimen of Ipertrofan are determined by the prescribing clinician based on the patient’s condition, severity, and individual health factors. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for Mepartricin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipertrofan (Mepartricin) belongs to the macrolide antibiotic class and offers both antibacterial and anti‑inflammatory actions, whereas many alternatives focus solely on one mechanism. Its dual activity can be advantageous in chronic prostatitis, but therapeutic choice should be individualized based on efficacy, safety profile and physician judgment.

Ipertrofan tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Ipertrofan is taken orally, typically with a full glass of water. The exact timing (e.g., with meals or on an empty stomach) should follow the prescribing physician’s guidance to optimize absorption and minimize gastrointestinal discomfort.

Serious adverse events, though rare, can include severe allergic reactions such as anaphylaxis, significant liver enzyme elevations, neutropenia, severe skin reactions like Stevens‑Johnson syndrome, and cardiac arrhythmias related to QT prolongation. Patients should seek immediate medical attention if any of these occur.

Ipertrofan is contraindicated in individuals with known hypersensitivity to Mepartricin or other macrolide antibiotics. Caution is also advised for patients with severe hepatic or renal impairment, and it should be avoided in pregnant women unless the potential benefit outweighs the risk.